24-242 Phase II
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab with Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab with Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
An Open-label, Multicenter, Phase 1, First in Human, Dose Escalation and Expansion Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
FEASIBILITY OF THE LUM IMAGING SYSTEM FOR DETECTION OF PERITONEAL SURFACE MALIGNANCIES
Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given orally as monotherapy in patients with unresectable metastatic KRAS wild type amplified gastric, oesophageal, and gastroesophageal-junction adenocarcinoma